Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Chronic Lymphocytic Leukemia
100%
Ibrutinib
42%
Richter Transformation
27%
COVID-19
26%
Fixation Duration
26%
Progression-free Survival
23%
Obinutuzumab
23%
Venetoclax
22%
Chlorambucil
21%
Rituximab
21%
Leukemia Patients
21%
BNT162b2
19%
Overall Survival
18%
Overall Response Rate
17%
Humoral Response
16%
Positron Emission Tomography/computed Tomography (PET/CT)
16%
Minimal Residual Disease
15%
Relapsed/refractory
15%
Chronic Lymphocytic Leukemia Cells
14%
Complete Response
14%
Frontline Therapy
13%
Vaccine Dose
13%
Randomized Phase III Trial
13%
Acute Myeloid Leukemia
12%
Non-Hodgkin Lymphoma
12%
Chimeric Antigen Receptor T Cells (CAR-T)
11%
Nave
11%
Vaccination
10%
Cyclin D1 (CCND1)
10%
Cyclophosphamide
10%
Fludarabine
10%
Monoclonal Antibody
10%
Chemoimmunotherapy
9%
Non-responders
9%
Previously Untreated
9%
Follicular Lymphoma
9%
Aggressive B-cell Lymphoma
8%
Bruton's Tyrosine Kinase Inhibitors (BTKi)
8%
Median Progression-free Survival
8%
Aggressive non-Hodgkin Lymphoma
8%
Antibody Response
8%
FDG PET-CT
8%
Treatment Lines
8%
Chronic Myeloid Leukemia
8%
Median Overall Survival
8%
Unfit Patients
8%
Initial Treatment
7%
BNT162b2 Vaccine
7%
Phase I Study
7%
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
7%
Medicine and Dentistry
B-Cell Chronic Lymphocytic Leukemia
75%
Ibrutinib
30%
Richter's Transformation
25%
Non-Hodgkin Lymphoma
25%
Overall Survival
24%
Diseases
21%
Progression Free Survival
20%
Positron Emission Tomography-Computed Tomography
19%
Chronic Lymphocytic Leukemia
16%
Humoral Immunity
13%
COVID-19 Vaccine
12%
B-Cell Lymphoma
12%
Acute Myeloid Leukemia
12%
Messenger RNA
12%
Infection
10%
Obinutuzumab
10%
Retrospective Study
9%
Hemoglobins
8%
Chlorambucil
8%
Rituximab
8%
Venetoclax
8%
Median Follow Up
8%
Tyrosine-Kinase Inhibitor
7%
Bruton Tyrosine Kinase Inhibitor
7%
B Cell
7%
Lymphocyte
7%
Large-Cell Lymphoma
7%
Myeloid Leukemia
6%
Allogeneic Stem Cell Transplantation
6%
Burkitt's Lymphoma
6%
NPM1
6%
Phase II Trials
6%
Observational Study
6%
Fungal Infection
6%
Leukemia Cell
6%
Dasatinib
6%
Acute Lymphoblastic Leukemia
6%
Philadelphia 1 Chromosome
6%
Hodgkin's Lymphoma
6%
Brentuximab Vedotin
6%
Mind-Body Interventions
6%
MALT Lymphoma
6%
Chimeric Antigen Receptor T-Cell Immunotherapy
6%
Bendamustine
6%
Chimeric Antigen Receptor T-Cell
6%
CAR T-cell therapy
6%
Clinical Trial Results
6%
Bevacizumab
6%
Kidney Graft
6%
Bisantrene
6%
Pharmacology, Toxicology and Pharmaceutical Science
Chronic Lymphatic Leukemia
59%
Ibrutinib
29%
Progression Free Survival
28%
Rituximab
21%
Diseases
21%
Obinutuzumab
17%
Venetoclax
14%
Acute Myeloid Leukemia
14%
Chlorambucil
14%
COVID-19 Vaccine
12%
Nonhodgkin Lymphoma
12%
Small Interfering RNA
11%
Cyclin D1
10%
Overall Survival
10%
Malignant Neoplasm
8%
Messenger RNA
8%
Fludarabine
8%
Cyclophosphamide
8%
Minimal Residual Disease
8%
Adverse Event
8%
Remission
7%
B Cell Lymphoma
7%
Follicular Lymphoma
6%
Protein Tyrosine Kinase Inhibitor
6%
Second Cancer
6%
Resveratrol
6%
Mantle Cell Lymphoma
6%
Bevacizumab
6%
Bisantrene
6%
Nanomedicine
6%
Clinical Trial Results
6%
microRNA 15a
6%
Bendamustine
6%
Solid Lipid Nanoparticle
6%
Observational Study
6%
Lenalidomide
6%